These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 35831042)

  • 1. Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study.
    Wang T; Li C; Li H; Li Z
    BMJ Open; 2022 Jul; 12(7):e057281. PubMed ID: 35831042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a Vaccine Passport Validation System Using Blockchain-based Architecture: Development Study.
    Lee HA; Wu WC; Kung HH; Udayasankaran JG; Wei YC; Kijsanayotin B; Marcelo AB; Hsu CY
    JMIR Public Health Surveill; 2022 Apr; 8(4):e32411. PubMed ID: 35377316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
    Rosero-Bixby L
    JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued effectiveness of COVID-19 vaccination among urban healthcare workers during delta variant predominance.
    Lan FY; Sidossis A; Iliaki E; Buley J; Nathan N; Bruno-Murtha LA; Kales SN
    BMC Infect Dis; 2022 May; 22(1):457. PubMed ID: 35549891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
    MacIntyre CR; Costantino V; Trent M
    Vaccine; 2022 Apr; 40(17):2506-2513. PubMed ID: 33958223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
    Kang M; Yi Y; Li Y; Sun L; Deng A; Hu T; Zhang J; Liu J; Cheng M; Xie S; Luo M; Jiang J; Jiang Y; Tang S; He J
    Ann Intern Med; 2022 Apr; 175(4):533-540. PubMed ID: 35099990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the India COVID-19 vaccine tracker.
    Singh H; Lohia R; George LS; Gupta N; Thangaraj JW; Rana S; Rana S; Kaur J; Shivam S; Arora NK; Muliyil JP; Murhekar MV; Lodha R; Pandey RM; Rao VV; Dhandore S; Malik A; Kumar V; Tripathi A; Panda S; Bhargava B
    Indian J Med Res; 2022; 155(5&6):513-517. PubMed ID: 35859397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes and personal beliefs about the COVID-19 vaccine among people with COVID-19: a mixed-methods analysis.
    Bennett MM; Douglas M; da Graca B; Sanchez K; Powers MB; Warren AM
    BMC Public Health; 2022 Oct; 22(1):1936. PubMed ID: 36258176
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 57.